DB-1421
/ DualityBio
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
March 18, 2026
DB-1421, an optimized EGFR/MUC1 bispecific ADC, exhibits improved tumor selectivity, promising efficacy and safety in preclinical studies
(AACR 2026)
- "DB-1421 is an EGFR/MUC1 bispecific ADC with a common light chain bispecific antibody and a DNA topoisomerase I inhibitor. Through rational design and engineer of EGFR and MUC1 binding arm, DB-1421 showed improved tumor selectivity, efficacy and very good safety. The promising efficacy and safety profile warrants further clinical development of DB-1421."
ADC • Bispecific • Preclinical • Breast Cancer • Colorectal Cancer • Esophageal Squamous Cell Carcinoma • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • Squamous Cell Carcinoma • EGFR • MUC1
1 to 1
Of
1
Go to page
1